{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T18:55:17Z","timestamp":1793472917030,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1136\/ard-2023-225445","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T17:20:12Z","timestamp":1712164812000},"page":"1018-1027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials"],"prefix":"10.1016","volume":"83","clinical-trial-number":[{"clinical-trial-number":"nct02446912","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02446899","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Tina","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda","family":"Sharifian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J","family":"Newcombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick G","family":"Gavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark N","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Ramaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy I","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Muthas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Tummala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9507-3338","authenticated-orcid":false,"given":"Eric F","family":"Morand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Furie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-4755","authenticated-orcid":false,"given":"Edward M","family":"Vital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Al-Mossawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip Z","family":"Brohawn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eszter","family":"Csomor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-225445_bib1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-101921-042422","article-title":"Systemic lupus erythematosus pathogenesis: interferon and beyond","volume":"41","author":"Caielli","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"10.1136\/ard-2023-225445_bib2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144918","article-title":"Bite of the wolf: innate immune responses propagate autoimmunity in lupus","volume":"131","author":"Gupta","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1136\/ard-2023-225445_bib3","doi-asserted-by":"crossref","DOI":"10.2217\/ijr.13.58","article-title":"Genetics of the type I interferon pathway in systemic lupus erythematosus","volume":"8","author":"Ghodke-Puranik","year":"2013","journal-title":"Int J Clin Rheumatol"},{"key":"10.1136\/ard-2023-225445_bib4","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1177\/0961203319885447","article-title":"Type I interferon gene signature test-low and -high patients with systemic lupus erythematosus have distinct gene expression signatures","volume":"28","author":"Brohawn","year":"2019","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-225445_bib5","article-title":"Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus","volume":"10","author":"Smith","year":"2020","journal-title":"Sci Rep"},{"key":"10.1136\/ard-2023-225445_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103025","article-title":"Distinct gene dysregulation patterns herald precision medicine potentiality in systemic lupus erythematosus","volume":"136","author":"Lindblom","year":"2023","journal-title":"J Autoimmun"},{"key":"10.1136\/ard-2023-225445_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002864","article-title":"Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider","volume":"9","author":"Rodr\u00edguez-Carrio","year":"2023","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-225445_bib8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/art.41518","article-title":"Modulation of cardiometabolic disease markers by type I interferon inhibition in systemic lupus erythematosus","volume":"73","author":"Casey","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225445_bib9","series-title":"SAPHNELO","author":"AstraZeneca","year":"2021"},{"key":"10.1136\/ard-2023-225445_bib10","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti\u2013Interferon\u2010\u03b1 receptor monoclonal antibody, in moderate\u2010to\u2010severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis & Rheumatology"},{"key":"10.1136\/ard-2023-225445_bib11","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2023-225445_bib12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-225445_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000286","article-title":"Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE","volume":"5","author":"Casey","year":"2018","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2023-225445_bib14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update on the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225445_bib16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/bioinformatics\/btv566","article-title":"Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data","volume":"32","author":"Okonechnikov","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1136\/ard-2023-225445_bib17","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The sequence alignment\/map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1136\/ard-2023-225445_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1136\/ard-2023-225445_bib19","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","article-title":"MultiQC: summarize analysis results for multiple tools and samples in a single report","volume":"32","author":"Ewels","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1136\/ard-2023-225445_bib20","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1186\/s12859-018-2579-2","article-title":"NGmerge: merging paired-end reads via novel empirically-derived models of sequencing errors","volume":"19","author":"Gaspar","year":"2018","journal-title":"BMC Bioinformatics"},{"key":"10.1136\/ard-2023-225445_bib21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware Quantification of transcript expression","volume":"14","author":"Patro","year":"2017","journal-title":"Nat Methods"},{"key":"10.1136\/ard-2023-225445_bib23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41592-018-0046-7","article-title":"Bioconda: sustainable and comprehensive software distribution for the life sciences","volume":"15","author":"Gr\u00fcning","year":"2018","journal-title":"Nat Methods"},{"key":"10.1136\/ard-2023-225445_bib24","author":"Coombes"},{"key":"10.1136\/ard-2023-225445_bib25","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/bioinformatics\/btaa687","article-title":"Dream: powerful differential expression analysis for repeated measures designs","volume":"37","author":"Hoffman","year":"2021","journal-title":"Bioinformatics"},{"key":"10.1136\/ard-2023-225445_bib26","author":"Blighe"},{"key":"10.1136\/ard-2023-225445_bib28","article-title":"clusterProfiler 4.0: A universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation (Camb)"},{"key":"10.1136\/ard-2023-225445_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24584-w","article-title":"Development of a fixed module repertoire for the analysis and interpretation of blood transcriptome data","volume":"12","author":"Altman","year":"2021","journal-title":"Nat Commun"},{"key":"10.1136\/ard-2023-225445_bib31","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.celrep.2019.01.041","article-title":"RNA-Seq signatures normalized by mRNA abundance allow absolute deconvolution of human immune cell types","volume":"26","author":"Monaco","year":"2019","journal-title":"Cell Rep"},{"key":"10.1136\/ard-2023-225445_bib32","author":"Pfister"},{"key":"10.1136\/ard-2023-225445_bib33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41579-018-0020-5","article-title":"ISG15 in antiviral immunity and beyond","volume":"16","author":"Perng","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"10.1136\/ard-2023-225445_bib34","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13075-018-1649-1","article-title":"The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus","volume":"20","author":"Oliveira","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-225445_bib35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41584-023-00948-y","article-title":"Precision medicine in systemic lupus erythematosus","volume":"19","author":"Fasano","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2023-225445_bib36","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.4049\/jimmunol.172.10.6362","article-title":"The transmembrane CXC-chemokine ligand 16 is induced by IFN-\u03b3 and TNF-\u03b1 and shed by the activity of the disintegrin-like metalloproteinase ADAM10","volume":"172","author":"Abel","year":"2004","journal-title":"J Immunol"},{"key":"10.1136\/ard-2023-225445_bib37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cyto.2016.08.003","article-title":"TNF activity and T cells","volume":"101","author":"Mehta","year":"2018","journal-title":"Cytokine"},{"key":"10.1136\/ard-2023-225445_bib38","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.4049\/jimmunol.0800185","article-title":"LAG-3 regulates plasmacytoid dendritic cell homeostasis","volume":"182","author":"Workman","year":"2009","journal-title":"J Immunol"},{"key":"10.1136\/ard-2023-225445_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000261","article-title":"Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus","volume":"5","author":"Riggs","year":"2018","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2023-225445_bib40","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","article-title":"Interferon target-gene expression and epigenomic signatures in health and disease","volume":"20","author":"Barrat","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1136\/ard-2023-225445_bib41","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1073\/pnas.1916897117","article-title":"Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus","volume":"117","author":"Goel","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/ard-2023-225445_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19918-z","article-title":"Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity","volume":"11","author":"Psarras","year":"2020","journal-title":"Nat Commun"},{"key":"10.1136\/ard-2023-225445_bib43","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.3899\/jrheum.190875","article-title":"Role of neutrophil extracellular traps regarding patients at risk of increased disease activity and cardiovascular comorbidity in systemic lupus erythematosus","volume":"47","author":"Moore","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-225445_bib44","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/ard.58.5.309","article-title":"Increased apoptotic peripheral blood neutrophils in systemic lupus erythematosus: relations with disease activity, antibodies to double stranded DNA, and neutropenia","volume":"58","author":"Courtney","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225445_bib45","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1359-6101(02)00006-0","article-title":"On the TRAIL to apoptosis","volume":"13","author":"Baetu","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1136\/ard-2023-225445_bib46","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/bjd\/ljad089","article-title":"Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers","volume":"189","author":"Carter","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard-2023-225445_bib47","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1684\/ejd.2012.1756","article-title":"CD163 expression is increased in the involved skin and sera of patients with systemic lupus erythematosus","volume":"22","author":"Nakayama","year":"2012","journal-title":"Eur J Dermatol"},{"key":"10.1136\/ard-2023-225445_bib48","doi-asserted-by":"crossref","first-page":"395","DOI":"10.5114\/ceji.2019.92795","article-title":"CD163 and CCR7 as markers for macrophage polarization in lung cancer microenvironment","volume":"44","author":"Kwiecie\u0144","year":"2019","journal-title":"Cent Eur J Immunol"},{"key":"10.1136\/ard-2023-225445_bib49","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00296-017-3888-x","article-title":"Monocyte chemoattractant protein-1 as a marker of systemic lupus erythematosus: an observational study","volume":"38","author":"\u017divkovi\u0107","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard-2023-225445_bib50","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13075-017-1257-5","article-title":"Activation status of mucosal-associated invariant T cells reflects disease activity and pathology of systemic lupus erythematosus","volume":"19","author":"Chiba","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-225445_bib51","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3389\/fimmu.2018.00756","article-title":"Unique and common features of innate-like human V\u03b42(+) \u0393\u03b4T cells and mucosal-associated invariant T cells","volume":"9","author":"Provine","year":"2018","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2023-225445_bib52","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.rdc.2021.04.005","article-title":"T cells in systemic lupus erythematosus","volume":"47","author":"Paredes","year":"2021","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1136\/ard-2023-225445_bib53","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1002\/art.11354","article-title":"B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations","volume":"48","author":"Stohl","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-225445_bib54","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/cei.12439","article-title":"CXCL13 as a new biomarker of systemic lupus erythematosus and lupus nephritis - from bench to bedside?","volume":"179","author":"Schiffer","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1136\/ard-2023-225445_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar3617","article-title":"Increased concentration of serum soluble LAG3 in systemic lupus erythematosus","volume":"14","author":"Yu","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-225445_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01619","article-title":"CD4+ CD25+ LAG3+ T cells with a feature of Th17 cells associated with systemic lupus erythematosus disease activity","volume":"10","author":"Kato","year":"2019","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2023-225445_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052424","article-title":"Dysregulated CD38 expression on peripheral blood immune cell subsets in SLE","volume":"22","author":"Burns","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1136\/ard-2023-225445_bib58","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-225445_bib59","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/annrheumdis-2021-221425","article-title":"Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials","volume":"81","author":"Vital","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225445_bib60","series-title":"Techniques in the Behavioral and Neural Sciences","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0921-0709(05)80017-3","article-title":"Chapter 3.2 - Glucocorticoid effects on gene expression","author":"Kino","year":"2005"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724000244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724000244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-225445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:17:13Z","timestamp":1739521033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724000244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0003496724000244"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-225445","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-225445","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc. on behalf of EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}